azacitidine has been researched along with gefitinib in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 9 (81.82) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Díaz-Montero, CM; Estecio, M; Issa, JP; Mao, L; Montero, AJ; Shen, L; Youssef, EM | 1 |
Dutkowski, C; Farrow, L; Fiegl, H; Gee, JM; McClelland, RA; McCloy, RA; Musgrove, EA; Nicholson, RI; Stone, A; Sutherland, RL; Valdés-Mora, F | 1 |
Cao, HX; Feng, JF; Li, XY; Ma, R; Wu, JQ; Wu, JZ; Zhong, YJ | 1 |
Chen, PJ; Huang, GB; Li, B; Lou, YF; Luo, XY; Yu, XR; Zheng, DQ; Zou, ZZ | 1 |
Gao, B; Li, GH; Shao, GG; Yang, B; Yang, ZG | 1 |
1 review(s) available for azacitidine and gefitinib
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for azacitidine and gefitinib
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line; Cell Line, Tumor; Decitabine; Dinucleoside Phosphates; DNA Methylation; DNA Primers; Epigenesis, Genetic; ErbB Receptors; Female; Gefitinib; Genetic Therapy; Humans; Organ Specificity; Quinazolines; Restriction Mapping; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.
Topics: Apoptosis; Azacitidine; Breast Neoplasms; Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Neoplasm; Growth Differentiation Factor 15; Humans; MCF-7 Cells; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Tamoxifen; Trefoil Factor-1; Tumor Suppressor Proteins | 2012 |
Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; CpG Islands; Decitabine; DNA Methylation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines | 2013 |
News products to avoid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur | 2014 |
Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Line, Tumor; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; Quinazolines | 2015 |